Alkem Laboratories has announced the launch of Pertuza injection 420mg/14mL, a pertuzumab biosimilar, in India for the treatment of HER2-positive breast cancer.
Developed and manufactured indigenously by Alkem and its biotech subsidiary, Pertuza offers a cost-effective alternative to the original pertuzumab treatment, addressing a critical accessibility challenge for cancer patients in India.
In its pivotal phase 3 clinical trial, Alkem’s pertuzumab biosimilar demonstrated equivalent efficacy, safety, and immunogenicity compared to the reference product of the innovator, ensuring that patients receive a reliable and scientifically validated therapy.
HER2-positive breast cancer treatment has traditionally been expensive, limiting access for many patients. With Pertuza, Alkem aims to make this life-saving therapy more affordable and widely available, supported by regulatory-compliant manufacturing and a strong oncology distribution network.
Alkem’s launch of Pertuza represents a significant step in improving cancer treatment accessibility in India, combining scientific credibility with patient-centric affordability.
